Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s Arxxant To Be Co-Promoted With Alcon

This article was originally published in The Pink Sheet Daily

Executive Summary

An FDA decision on the potential first-in-class diabetic retinopathy treatment is expected next month.

You may also be interested in...



Fate Of Speedel’s Diabetic Nephropathy Drug May Be Clearer Mid-Year 2007

DSMB halts Phase III trial of SPP301 due to an imbalance of fluid retention in patients in the study arms.

Fate Of Speedel’s Diabetic Nephropathy Drug May Be Clearer Mid-Year 2007

DSMB halts Phase III trial of SPP301 due to an imbalance of fluid retention in patients in the study arms.

Arxxant’s Fate In Question After FDA Requests Additional Trial

Lilly may seek a development partner for the diabetic retinopathy treatment to collect the three additional years of efficacy data sought by FDA.

Related Content

Topics

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel